tiprankstipranks
Trending News
More News >
Amvis Holdings.Inc. (JP:7071)
:7071
Japanese Market
Advertisement

Amvis Holdings.Inc. (7071) AI Stock Analysis

Compare
1 Followers

Top Page

JP:7071

Amvis Holdings.Inc.

(7071)

Select Model
Select Model
Select Model
Neutral 64 (OpenAI - 4o)
Rating:64Neutral
Price Target:
¥610.00
▲(17.99% Upside)
Amvis Holdings Inc. demonstrates strong financial performance with significant revenue growth and profitability. However, technical indicators suggest bearish momentum, and cash flow challenges pose potential risks. The stock is reasonably valued, but investors should be cautious of the downward trend and focus on the company's ability to manage its cash flow effectively.

Amvis Holdings.Inc. (7071) vs. iShares MSCI Japan ETF (EWJ)

Amvis Holdings.Inc. Business Overview & Revenue Model

Company DescriptionAmvis Holdings, Inc. provides nursing home, home nursing care, home care, in-home care support, and disability welfare services in Japan. It also offers consulting and other ancillary services. The company was founded in 2013 and is headquartered in Tokyo, Japan.
How the Company Makes MoneyAmvis Holdings generates revenue through a multi-faceted model, primarily by acquiring stakes in high-potential companies within its sectors of interest. The company earns income through dividends from its investments, capital gains from the appreciation of its holdings, and fees for services rendered by its subsidiaries. Additionally, Amvis engages in strategic partnerships that allow for collaborative projects and shared resources, further enhancing its revenue streams. Its focus on technology and innovation positions it to capitalize on emerging market trends, which can lead to significant financial returns.

Amvis Holdings.Inc. Financial Statement Overview

Summary
Amvis Holdings Inc. shows strong revenue growth and profitability with a 32.8% increase in revenue and solid margins. However, the balance sheet reveals rising debt levels, and cash flow management is a concern with zero free cash flow reported, indicating a need for strategic improvements.
Income Statement
85
Very Positive
Amvis Holdings Inc. demonstrates robust financial performance with steady revenue growth, as indicated by a significant TTM revenue of 44.7 billion JPY compared to 31.9 billion JPY in the previous annual period, marking a growth rate of approximately 32.8%. The gross profit margin remains strong at 38.3% in TTM, reflecting effective cost management. The net profit margin is healthy at 15.6% in TTM, though there has been a slight decline from previous periods, suggesting some pressure on net income. EBIT and EBITDA margins are also solid at 22.3% and 26.5% respectively, showcasing operational efficiency.
Balance Sheet
78
Positive
The balance sheet of Amvis Holdings Inc. indicates a strong equity position with a debt-to-equity ratio of 0.99 in TTM, which is manageable, though it has increased compared to previous years. The company's equity ratio stands at 45.9%, reflecting a balanced capital structure. Return on equity is impressive at 20.6% in TTM, indicating effective use of shareholder funds. However, the increased total debt level may pose potential risks if not managed carefully.
Cash Flow
60
Neutral
Cash flow analysis reveals challenges, as the company reports a zero free cash flow in TTM, indicating issues in cash generation after investments. The operating cash flow to net income ratio is unavailable due to missing data, which makes it difficult to assess cash flow efficiency. Historical data shows a negative trend in free cash flow, highlighting the need for improved cash management.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue46.70B42.48B31.98B23.07B15.33B9.17B
Gross Profit16.71B17.06B13.27B9.69B6.30B3.75B
EBITDA11.56B12.76B10.39B7.10B4.48B2.17B
Net Income6.33B7.44B6.31B4.28B2.63B1.24B
Balance Sheet
Total Assets82.68B71.80B55.56B41.77B31.92B16.52B
Cash, Cash Equivalents and Short-Term Investments11.81B8.87B12.13B11.34B11.19B3.33B
Total Debt40.32B31.75B23.05B17.43B12.75B9.55B
Total Liabilities47.52B38.59B29.04B21.31B15.58B11.27B
Stockholders Equity35.16B33.21B26.52B20.46B16.34B5.25B
Cash Flow
Free Cash Flow0.00-8.52B-3.06B-2.73B-2.79B-3.78B
Operating Cash Flow0.007.48B6.80B4.42B2.58B1.17B
Investing Cash Flow0.00-16.83B-10.31B-7.75B-5.78B-5.30B
Financing Cash Flow0.006.08B4.30B3.49B11.05B7.02B

Amvis Holdings.Inc. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price517.00
Price Trends
50DMA
620.55
Negative
100DMA
554.24
Positive
200DMA
558.34
Positive
Market Momentum
MACD
-8.33
Positive
RSI
46.76
Neutral
STOCH
58.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7071, the sentiment is Negative. The current price of 517 is below the 20-day moving average (MA) of 604.80, below the 50-day MA of 620.55, and below the 200-day MA of 558.34, indicating a neutral trend. The MACD of -8.33 indicates Positive momentum. The RSI at 46.76 is Neutral, neither overbought nor oversold. The STOCH value of 58.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7071.

Amvis Holdings.Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
80
Outperform
¥48.79B11.384.00%1.43%
79
Outperform
¥20.85B11.913.40%4.31%-9.01%
76
Outperform
€48.67B20.1820.78%1.61%15.78%-7.51%
70
Outperform
¥35.91B14.4737.50%-22.93%
64
Neutral
¥57.71B16.000.68%15.60%-51.75%
63
Neutral
¥35.48B12.103.03%-2.42%-31.36%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:7071
Amvis Holdings.Inc.
586.00
-1,279.64
-68.59%
JP:6099
Elan Corp.
809.00
-34.90
-4.14%
JP:2374
Saint-Care Holding Corp.
883.00
178.08
25.26%
JP:6062
Charm Care Corporation
1,121.00
-97.23
-7.98%
JP:6197
Solasto Corp.
525.00
61.45
13.26%
JP:9158
CUC Inc.
1,171.00
-374.00
-24.21%

Amvis Holdings.Inc. Corporate Events

Amvis Holdings Revises Financial Forecast Amid Operational Disruptions
Oct 20, 2025

Amvis Holdings, Inc. announced corrections to its previously disclosed Consolidated Financial Summary for the first nine months of the fiscal year ending September 30, 2025, due to identified inaccuracies. The company revised its full-year earnings forecast downward, citing disruptions caused by staff reassignment for an investigation, which impacted service provision and sales.

The most recent analyst rating on (JP:7071) stock is a Buy with a Yen665.00 price target. To see the full list of analyst forecasts on Amvis Holdings.Inc. stock, see the JP:7071 Stock Forecast page.

Amvis Holdings Revises Earnings Forecast Amid Operational Challenges
Oct 17, 2025

Amvis Holdings, Inc. has revised its full-year earnings forecast for the fiscal year ending September 30, 2025, due to recent performance trends and operational challenges. The company anticipates a decrease in net sales, operating profit, ordinary profit, and profit attributable to owners of the parent compared to previous forecasts, largely due to staff reassignments for a special investigation, affecting service provision and occupancy adjustments.

The most recent analyst rating on (JP:7071) stock is a Buy with a Yen665.00 price target. To see the full list of analyst forecasts on Amvis Holdings.Inc. stock, see the JP:7071 Stock Forecast page.

Amvis Holdings Reports Decline in Profits Despite Sales Growth
Oct 17, 2025

Amvis Holdings, Inc. reported a decline in profits for the first nine months of the fiscal year ending September 30, 2025, despite an increase in net sales. The company experienced a significant decrease in EBITDA, operating profit, and profit attributable to owners of the parent, reflecting challenges in maintaining profitability. The financial forecast for the fiscal year anticipates continued pressure on profits, with a notable decrease expected in profit attributable to owners of the parent. The inclusion of a new company, Midori, in the scope of consolidation marks a strategic move, although the overall financial outlook remains cautious.

The most recent analyst rating on (JP:7071) stock is a Buy with a Yen665.00 price target. To see the full list of analyst forecasts on Amvis Holdings.Inc. stock, see the JP:7071 Stock Forecast page.

Amvis Holdings Sets New Date for Q3 Financial Results
Sep 9, 2025

Amvis Holdings, Inc. has announced a new date for the release of its financial results for the third quarter of the fiscal year ending September 2025, which will now be disclosed on October 17, 2025. The company had previously delayed the announcement, causing inconvenience and concern among stakeholders, for which it has apologized.

The most recent analyst rating on (JP:7071) stock is a Buy with a Yen673.00 price target. To see the full list of analyst forecasts on Amvis Holdings.Inc. stock, see the JP:7071 Stock Forecast page.

Amvis Holdings Announces Improvement Measures Following Investigation
Aug 14, 2025

Amvis Holdings, Inc. has announced a series of improvement measures following an investigation into its operations, prompted by media reports of potential improper medical fee claims. The investigation found no organizational misconduct but highlighted areas needing improvement. In response, Amvis is implementing measures to define and standardize home-visit nursing services, enhance recruitment and staffing systems, rebuild internal controls, and improve internal communication. These initiatives aim to strengthen the company’s operational efficiency and compliance, ultimately benefiting stakeholders by ensuring accurate service delivery and robust internal processes.

Amvis Holdings Completes Semi-Annual Report Submission
Aug 14, 2025

Amvis Holdings, Inc. has announced the completion of its semi-annual report submission for the fiscal year ending September 30, 2025, following an approved extension. The company expressed apologies for any inconvenience caused by the delay, emphasizing its commitment to maintaining transparency and accountability with its stakeholders.

Amvis Holdings Delays Third Quarter Financial Results Disclosure
Aug 14, 2025

Amvis Holdings, Inc. announced a delay in the disclosure of its financial results for the third quarter of the fiscal year ending September 30, 2025. The delay, expected to exceed 45 days post-quarter, is due to the time required to complete procedures related to the financial results. This postponement may cause inconvenience and concern among stakeholders, but the company assures that the specific date for the announcement will be disclosed promptly once determined.

Amvis Holdings Reports Profit Decline Amid Sales Growth
Aug 14, 2025

Amvis Holdings, Inc. reported a decline in profits for the first six months of the fiscal year ending September 30, 2025, despite an increase in net sales. The company’s operating profit and profit attributable to owners of the parent decreased significantly compared to the previous year, indicating challenges in maintaining profitability. The company also announced the inclusion of a new subsidiary, Midori, in its consolidated financial statements, reflecting strategic expansion efforts.

Amvis Holdings Receives Investigation Report on Billing Allegations
Aug 8, 2025

Amvis Holdings, Inc. has received an investigation report from a Special Investigation Committee, which was formed to examine allegations of improper billing of medical fees. The investigation found no evidence of systematic misconduct, and the financial impact is minor, amounting to approximately ¥63 million. The company acknowledges deficiencies in its internal systems and is committed to improvements, including organizational restructuring and enhanced recordkeeping. The findings have caused concern among stakeholders, and Amvis plans to disclose further initiatives at its upcoming earnings announcement.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 22, 2025